Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties.

R. Taguchi,Koki Hatayama,Tomohito Takahashi,Takafumi Hayashi,Yuki Sato,D. Sato,K. Ohta,H. Nakano,Chigusa Seki,Y. Endo,K. Tokuraku,K. Uwai

DOI: https://doi.org/10.1016/j.ejmech.2017.07.026

IF: 7.088

2017-09-29

European Journal of Medicinal Chemistry

Abstract:

What problem does this paper attempt to address?

Wireless wideband SAW sensor - antenna design

M. Gallagher,B. Santos,D. Malocha

DOI: https://doi.org/10.1109/FREQ.2010.5556326

2010-06-01

Abstract:Wireless SAW RFID sensors offer several advantages over similar silicon technology that include passive operation, radiation hardness, and the ability to operate in extreme temperatures. Due to these unique material and device properties, NASA has shown considerable interest in passive, wireless SAW sensors for ground and space flight operations. Several embodiments of SAW sensors have been well established in literature, but often the limiting factor on device size and performance is the tag antenna. Therefore, in order to develop a unified sensor target, a discussion of design principles and tradeoffs for both the SAW device and antenna will be presented in this paper. Antennas designed and fabricated will be presented, including a simple disk monopole, a planar open-sleeve dipole, and an on-wafer meandered dipole, with a discussion on gain, size, and bandwidth. The evolution of the antenna design is toward smaller antennas that minimize tradeoffs. The eventual wafer level integration of the antenna allows the sensor application to exploit some of the known SAW substrate advantages and has application in high temperature or strain sensors. Example orthogonal frequency coded (OFC) temperature sensors on YZ-LiNbO3 for use at 250 and 915MHz will be used as device examples. By properly designing the combined antenna/SAW target matching, insertion loss can be minimized and range increased. Experimental results on the integration of several sensor targets will be presented. Work presented is a foundation for a realizable wireless, multi-sensor platform.
Low-flow mediated constriction incorporated indices as indicators of cardiovascular risk in smokers.

N. Norioka,Y. Takemoto,Masanori Kobayashi,Ayako Makuuchi,J. Yoshikawa,Yoichi Yamazaki,Y. Kamiyama,T. Shuto,M. Yoshiyama

DOI: https://doi.org/10.1016/j.atherosclerosis.2016.06.022

IF: 5.3

2016-08-01

Atherosclerosis

Abstract:
Hepatitis B immune globulin (HBIG): efficacy in the interruption of vertical transmission of hepatitis B virus (HBV) carrier state.

D. Pongpipat,V. Suvatte,A. Assateerawatts

Journal of the Medical Association of Thailand = Chotmaihet thangphaet

Abstract:
Letrozole Stimulation in Endometrial Preparation for Cryopreserved–thawed Embryo Transfer in Women with Polycystic Ovarian Syndrome: A Pilot Study

Yan-Jun Hu,Yue-Zhou Chen,Yi-Min Zhu,He-Feng Huang

DOI: https://doi.org/10.1111/cen.12280

2013-01-01

Clinical Endocrinology

Abstract:OBJECTIVE:To study the efficiency of letrozole, an aromatase inhibitor, in endometrial preparation for cryopreserved-thawed embryo transfer (FET) in women with polycystic ovarian syndrome (PCOS).DESIGN:Retrospective observational study.PATIENTS:One hundred and twenty patients with PCOS who met the inclusion criteria for the study.MEASUREMENTS:We assessed in vitro fertilization outcomes in one hundred and twenty patients with PCOS (148 cycles) who were prepared for and underwent FET between June 2011 and December 2012. Patients were prepared for FET using artificial hormone cycles induced with oestrogen and progesterone supplementation (n = 76), letrozole stimulation (n = 40) or hMG stimulation (n = 32).RESULTS:There were no differences in demographic characteristics between the groups, except that the letrozole group had a higher incidence of embryo transfer failure in the past. The letrozole stimulation group had a significantly higher maximal endometrial thickness and significantly higher rates of clinical pregnancy per transfer, ongoing pregnancy per transfer and implantation, compared with the artificial and hMG stimulation groups. Differences in these parameters between the artificial and hMG stimulation groups were not significant.CONCLUSION:Using letrozole stimulation in endometrial preparation for cryopreserved-thawed embryo transfer in patients with PCOS may be associated with better outcomes than using hormonal manipulation or hMG stimulation.
Letrozole Combined With Oral Contraceptives Versus Oral Contraceptives Alone In The Treatment Of Endometriosis-Related Pain Symptoms: A Pilot Study

Yi Zhao,Xiaofei Luan,Yuya Wang

DOI: https://doi.org/10.1080/09513590.2020.1807502

2021-01-01

Gynecological Endocrinology

Abstract:Background: To compare the efficacy and the tolerability of letrozole combined with oral contraceptives versus oral contraceptives alone in treating endometriosis-related pain.Methods: A total of 820 women with endometriosis presented with endometriosis-related pain were enrolled with this study. Patients were randomly treated either with letrozole (2.5 mg/day) combined with oral contraceptives (Desogestrel and Ethinylestradiol Tablets)or oral contraceptives (Desogestrel and Ethinylestradiol Tablets) alone for 6 months. Changes in pain symptoms during treatment and in 1 months after treatment, 6-month follow-up and 12-month follow-up were evaluated. Adverse effects of each treatment protocol were recorded.Results: At completion of treatment, the intensity of chronic pelvic pain continued to decrease during treatment and at 1-month after treatment it was significantly lower than at 6-month follow-up and baseline level both in LE + oral contraceptives group (Mean +/- SD,1.5 +/- 1.4) and in oral contraceptives alone group(Mean +/- SD,2.9 +/- 1.2).The intensity of chronic pelvic pain and deep dyspareunia was significantly decrease at both 1-month after treatment and 6-month follow-up.Conclusions: This treatment for endometriosis is a promising new modality that warrants further investigation.
Efficacy of N-Acetylcysteine on Endometriosis-Related Pain, Size Reduction of Ovarian Endometriomas, and Fertility Outcomes

Emanuela Anastasi,Sara Scaramuzzino,Maria Federica Viscardi,Valentina Viggiani,Maria Grazia Piccioni,Laura Cacciamani,Lucia Merlino,Antonio Angeloni,Ludovico Muzii,Maria Grazia Porpora

DOI: https://doi.org/10.3390/ijerph20064686

2023-03-07

Abstract:Background: Endometriosis is a chronic, estrogen-dependent, inflammatory disease, whose pivotal symptoms are dysmenorrhea, dyspareunia, and chronic pelvic pain (CPP). Besides the usual medical treatments, recent evidence suggests there are potential benefits of oral N-acetylcysteine (NAC) on endometriotic lesions and pain. The primary objective of this prospective single-cohort study was to confirm the effectiveness of NAC in reducing endometriosis-related pain and the size of ovarian endometriomas. The secondary objective was to assess if NAC may play a role in improving fertility and reducing the Ca125 serum levels. Methods: Patients aged between 18-45 years old with a clinical/histological diagnosis of endometriosis and no current hormonal treatment or pregnancy were included in the study. All patients received quarterly oral NAC 600 mg, 3 tablets/day for 3 consecutive days of the week for 3 months. At baseline and after 3 months, dysmenorrhea, dyspareunia and CPP were assessed using the Visual Analog Scale score (VAS), while the size of the endometriomas was estimated through a transvaginal ultrasound. Analgesics (NSAIDs) intake, the serum levels of Ca125 and the desire for pregnancy were also investigated. Finally, the pregnancy rate of patients with reproductive desire was evaluated. Results: One hundred and twenty patients were recruited. The intensity of dysmenorrhea, dyspareunia and CPP significantly improved (p < 0.0001). The use of NSAIDs (p = 0.001), the size of the endometriomas (p < 0.0001) and the serum levels of Ca125 (p < 0.0001) significantly decreased. Among the 52 patients with reproductive desire, 39 successfully achieved pregnancy within 6 months of starting therapy (p = 0.001). Conclusions: Oral NAC improves endometriosis-related pain and the size of endometriomas. Furthermore, it decreases Ca125 serum levels and may improve fertility in patients with endometriosis.
Comparing the effectiveness of letrozole versus methotrexate for treatment of ectopic pregnancy: A randomized controlled trial

Azadeh Tarafdari,Saeedeh Eslami Khotbesara,Fatemeh Keikha,Mohammadamin Parsaei,Marzie Poorabdoli,Henry H Chill,Alireza Hadizadeh

DOI: https://doi.org/10.1016/j.ejogrb.2024.06.026

Abstract:Objective: To evaluate the efficacy of two different regimens of Letrozole, an aromatase inhibitor, in the management of ectopic pregnancy compared to methotrexate. Study design: This randomized controlled trial was conducted on 88 women diagnosed with ectopic pregnancy with a baseline level of serum beta-human chorionic gonadotropin under 3000 mIU/mL between June 30, 2023, and December 30, 2023, at the Department of Obstetrics and Gynecology of the Vali-e-Asr Hospital affiliated with Tehran University of Medical Sciences. Participants were allocated into either methotrexate (n = 43), 5-day course Letrozole (n = 24), or 10-day course Letrozole (n = 21) treatments. The methotrexate group received a single dose of 50 mg/m2 dosage intramuscular methotrexate. The 5-day Letrozole group received a 2.5 mg Letrozole tablet three times daily for 5 days, whereas the 10-day Letrozole group received a 2.5 mg Letrozole tablet twice daily for 10 days. The primary outcome was the treatment response, defined as the achievement of a negative serum beta-human chorionic level without the need for additional methotrexate treatment or surgery. The secondary outcomes were the need for additional methotrexate dose or laparoscopic surgery intervention. The trial protocol was prospectively registered in ClinicalTrials.gov with code NCT05918718. Results: The treatment response rates in methotrexate, 5-day Letrozole, and 10-day Letrozole groups were 76.7 %, 75.0 %, and 90.5 %, respectively, with no significant differences between the groups (P-value = 0.358). A total of 10 (23.3 %) patients from the methotrexate group, 3 (12.5 %) from the 5-day Letrozole group, and 2 (9.5 %) from the 10-day Letrozole group required an additional methotrexate dose, with no significant differences between the groups (P-value = 0.307). Furthermore, only 3 (12.5 %) patients, all from the 5-day Letrozole group, were suspected of tubal rupture and underwent surgery (P-value = 0.016). Conclusion: Our findings suggest Letrozole as a safe alternative to methotrexate in treating stable ectopic pregnancies, with a favorable treatment response rate. However, there is still a need for future larger studies to determine the applicability of Letrozole in the EP management. Also, the non-significant higher effectiveness of the 10-day Letrozole regimen than the 5-day Letrozole group underscores the need for future research to determine the optimal Letrozole regimen for the management of ectopic pregnancy.
Does Nomegestrol Acetate Plus 17β-Estradiol Oral Contraceptive Improve Endometriosis-Associated Chronic Pelvic Pain in Women?

Salvatore Caruso,Antonio Cianci,Marco Iraci,Valentina Fava,Salvatore Di Pasqua,Stefano Cianci

DOI: https://doi.org/10.1089/jwh.2020.8291

2020-09-01

Abstract:Background: To evaluate the effects of a 24/4 regimen combined oral contraceptive (COC) containing 1.5 mg 17β-estradiol (E2) and 2.5 mg nomegestrol acetate (NOMAC) compared to on-demand nonsteroidal anti-inflammatory drugs (NSAIDs) on women affected by endometriosis-associated chronic pelvic pain (the primary end point) and their quality of life (QoL) and sexual function (the secondary end points).Materials and Methods: Ninety-nine women on E2/NOMAC constituted the study group; and 63 women on NSAIDs constituted the control group. The visual analogic scale was used to measure the levels of pelvic pain, dysmenorrhea, and dyspareunia. To assess their QoL, sexual function, and sexual distress, the Short Form-36 (SF-36), the Female Sexual Function Index (FSFI), and the Female Sexual Distress Scale (FSDS) were used, respectively. The study included two follow-ups at 3 and 6 months.Results: Improvement in chronic pelvic pain was observed in the study group at both the 3- and 6-month follow-ups (p < 0.001). SF-36, FSFI, and FSDS had a similar trend at the 3- and 6-month follow-ups (p < 0.001). Women on NSAIDs did not report any reduction in pain symptoms or improvement in QoL (p ≤ 0.4). However, they had a limited improvement of their FSFI and FSDS (p < 0.001). The improvement of the pain symptoms, QoL, FSFI, and FSDS, was more evident in women on E2/NOMAC than in those on NSAIDs, when the study group and control group values were compared at the 3- and 6-month follow-ups (p < 0.001).Conclusions: Women on E2/NOMAC COC showed a better reduction of endometriosis-associated chronic pelvic pain and an improvement of their QoL and sexual activity than those of the women on NSAIDs.
Beta3-adrenoceptor is involved in the inhibition of small intestinal motility due to restraint stress in rats.

F. Tsukada,M. Sugawara,K. Sawamura,Y. Ohuchi,H. Kohno,Y. Ohkubo

DOI: https://doi.org/10.1248/BPB.24.995

2001-09-01

Biological and Pharmaceutical Bulletin

Abstract:We have reported that acute restraint stress inhibits small intestinal motility in rats. In order to clarify this inhibitory mechanism, we examined the effects of alpha- and beta-adrenergic antagonists on the inhibition of small intestinal motility induced by restraint stress. This inhibition underwent recovery by propranolol (beta1/beta2-antagonist) or SR59230A (beta3-antagonist), but not by atenolol (beta1-antagonist), ICI-118,551 (beta2-antagonist), prazosin (alpha1-antagonist) or yohimbine (alpha2-antagonist). These results suggest that beta3-adrenoceptors play an important role in the inhibition of small intestinal motility caused by restraint stress.
Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer.

M. Veslemes,D. Antoniou,N. Georgatou,P. Giamboudakis,J. Dimitroulis,K. Katis,G. Stathopoulos

2005-07-01

Anticancer Research

Abstract:BACKGROUND The aim of this study was to evaluate the effectiveness of cisplatin- (CDDP) combined chemotherapy in non-cisplatin pretreated patients with non-small-cell lung cancer (NSCLC). The second cytotoxic drug administered was either etoposide or gemcitabine. First-line treatment was based on paclitaxel combined with either carboplatin or vinorelbine. PATIENTS AND METHODS Seventy-eight patients with histologically- or cytologically- confirmed NSCLC, having failed front-line treatment, were enrolled. All patients received 80 mg/m2 of cisplatin as second-line treatment, on day 1, repeated every 3 weeks; in 48 patients the second agent was etoposide (120 mg/m2) on days 1, 2 and 3, repeated every 3 weeks and in 30 patients 1 g/m2 of gemcitabine on day 1, repeated every 3 weeks. RESULTS All patients were evaluable for response and toxicity. No complete responses were observed. Thirteen (16.67%) patients achieved partial response, 42 (53.85%) stable disease and 23 (29.49%) had disease progression. The median duration of response was 4 months (range 2-8+ months), median time to tumor progression (TTP) 5 months (range 2-9 months) and median survival time after starting second-line chemotherapy, 6 months (range 2-9+ months). Toxicity was acceptable: 9 patients presented with nephrotoxicity (11.54%) and 13 (16.67%) with grade 3-4 neutropenia. CONCLUSION The cisplatin combination as second-line treatment in patients with NSCLC exhibited a notable degree of activity and tumor growth control was evidenced by the 16.67% partial response and 53.85% disease stability.
Electronic structure of the neutral manganese acceptor in gallium arsenide.

Schneider,Kaufmann,Wilkening,Baeumler,Köhl

DOI: https://doi.org/10.1103/PHYSREVLETT.59.240

IF: 8.6

1987-07-13

Physical Review Letters

Abstract:A new maganese-related isotropic electron-spin-resonance signal at g=2.77 has been observed in GaAs. It is shown to arise from the neutral Mn acceptor, ${\mathrm{Mn}}^{0}$. The analysis gives an answer to the longstanding question of whether the structure of ${\mathrm{Mn}}^{0}$ correponds to the 3${\mathrm{d}}^{4}$ or to the 3${\mathrm{d}}^{5}$+hole. The data clearly favor the latter case, thus revealing that Mn is an exception within the 3d acceptor family in GaAs.
Efficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysis

Antonio Simone Laganà,Andrea Etrusco,Joe Haydamous,Samar Semaan,Vittorio Agrifoglio,Vito Chiantera,Amerigo Vitagliano,Gaetano Riemma,Antonio D'Amato,Erik Montagna

DOI: https://doi.org/10.1016/j.ejogrb.2024.06.043

Abstract:Background: Tubal ectopic pregnancy (EP) is a life-threatening condition, especially if undiagnosed or misdiagnosed, tipically in low income countries and/or where women have limited access to health care. The current management protocol of tubal EP consists of either surgical management, or medical management with methotrexate. Recent studies, while few, have suggested that letrozole, an aromatase inhibitor, may play a role in the medical treatment of tubal EP. Objectives: To evaluate the effectiveness of letrozole alone in the medical treatment of tubal EP. Search strategy: Electronic databases were searched until 31 December 2023. Selection criteria: Retrospective or prospective studies reporting the treatment of tubal EP with letrozole alone were considered eligible for inclusion. Data collection and analysis: Pooled results were expressed as OR with 95 %CI. Heterogeneity was assessed using Higgins I2. Subgroup analysis was performed to compare outcomes according to time after intervention. Subgroup differences were checked through χ2 test. Results: A total of 152 patients were included. Seventy-nine patients (51.97 %) were treated with letrozole, 39 patients (16.54 %) with methotrexate, and 34 patients (31.49 %) underwent surgical treatment. Pooled data analysis supports the consistency of the effect of letrozole in reducing β-hCG over time at a comparable rate among studies, and that treatment with letrozole is superior to surgery and has the same efficacy as methotrexate. However, all the included studies were judged at high risk of bias in terms of study design, sample representativeness, and sampling technique. Furthermore, short and long term side effects were not reported in any of the included studies. Conclusions: Letrozole is a promising alternative to methotrexate and surgical therapy in the treatment of tubal EP. Although this meta-analysis suggests efficacy and low hazard of the drug and encourages its application, the data available today remain extremely sparse, which weakens any claims that can be made, and is not sufficient to assert that letrozole is safe and effective in the treatment of EPs. There is an absolute need for randomized studies with accurate patient selection, fixed doses, large sample sizes, and reporting of short- and long-term side effects to refute or confirm this assumption.
Randomized,blind,parallel-controlled and multiple-centre clinical trial on the effectiveness and safety of leuprolide acetate in the treatment of endometriosis

CHEN Qing-yun,BIAN Mei-lu,Jie Qiao,ZHANG Zhen-yu,LIN Jin-fang,ZUO Yue-wei

2015-01-01

Abstract:Objective: To evaluate the effectiveness and safety of leuprolide acetate in the treatment of endometriosis.Methods: The patients with confirmed endometriosis were randomly divided into leuprolide(n=75) and control(n=74) groups.They were treated with either sustained-release injection of leuprolide acetate or Enatntone injection(control) for 3 times totally.After treatment,the ovarian mass volume was measured under B ultrasound;the changes in hormones(E2,FSH,LH),the pelvic signs,the scores of the patient's subjective symptoms during menstruation and non-menstrual days were observed.Results: The rates of changes in ovarian mass volume had no statistically significant difference between the two groups(P=0.495~0.965).The median of ovarian mass volume reduce rate was-62.14% in the test group,and it was-68.83% in the control group at 12 weeks after the treatments.The distinct improvement rates and improvement rates of total symptom scores during menstruation and non-menstrual days had no statistically significant difference between the two groups.Hormone(E2,FSH,LH) levels were reached the level of menopause,and returned to normal when menstruation resumed after treatment;there was no significant difference between the two groups.The difference in the incidence of adverse reactions between the two groups was not significant.Conclusion: Leuprolide acetate is effective and safe in the treatment of endometriosis.
A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women

Zheng Li,Hong Yuan Zhang,Ying Jun Zhu,Yuan Jing Hu,Peng Peng Qu

DOI: https://doi.org/10.1016/j.ejogrb.2014.10.022

Abstract:Objectives: Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestrogenic status after treatment of leuprorelin and triptorelin in Chinese women with ovarian endometrioma after conservative surgical treatment. Study design: A total of 302 women underwent laparoscopic excision of ovarian endometriomas with rASRM III and IV were enrolled in the study.Subjects were randomized into two groups with use of a random table. Twenty two patients dropped out during the study. Thus 142 patients had three doses of i.m. leuprorelin (group A) and 138 patients had three doses of i.m. triptorelin(group B) at 4 weeks intervals after surgical treatment. Menopausal symptoms were evalutaed using a questionnaire and serum sex hormonal levels were also measured during the follow-up. Results: At week 4 after the treatment, most of the patients in leuprorelin group have no obvious side effects. After 9 weeks, bone pain, hot flashes and sweating, and irregular bleeding were the main side effects and showed no difference between the groups. Anxiety, depression, vaginal dryness, headache, and acne rates were all significantly higher in triptorelin group than in leuprorelin group. A significant difference in FSH (p=0.003), LH (p=0.026) and E2 (p=0.002) levels between the groups were observed after 21 days of the GnRHa treatment. The FSH (p=0.021) and E2 (p=0.033) levels remained higher in the leuprorelin group than the triptorelin group after six weeks of treatment, but the difference of LH(p=0.917) level was no longer discernible. Conclusion: Leuprorelin in down-regulating the pituitary-ovarian function was more moderate, and the hormonal levels decrease progressively and gradually, therefore, with lower rate of menopausal symptoms. Leuprorelin acetate maybe better tolerated than triptorelin.
Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

D. W. Sturdee,D. F. Archer,V. Rakov,E. Lang,on behalf of the CHOICE Study Investigators,on behalf of the CHOICE Study Inves

DOI: https://doi.org/10.1080/13697130701852390

2008-01-01

Climacteric

Abstract:OBJECTIVE: To evaluate the effect of two ultra-low-dose hormone treatments containing estradiol (E2) 0.5 mg and norethisterone acetate (NETA) 0.1 or 0.25 mg on the endometrium and bleeding.METHODS: A prospective, randomized, placebo-controlled trial of 6 months. Local Ethics Committee approval and informed consent were obtained prior to initiation and enrollment. Out of 577 postmenopausal women randomized, 575 took E2/NETA 0.1 (n = 194), or E2/NETA 0.25 (n = 181) or placebo (n = 200). Endometrial bleeding was monitored by daily diary cards and endometrial thickness by transvaginal ultrasound at baseline and on completion. An endometrial biopsy was obtained when indicated clinically.RESULTS: In months 1-6, the amenorrhea rates with E2/NETA 0.1 were 89%, 89%, 86%, 85%, 89% and 89%, respectively and the no-bleeding rates were correspondingly high: 95%, 94%, 93%, 90%, 95% and 95%. The amenorrhea and spotting-only rates were similar with both ultra-low-dose combinations. The withdrawal rates due to bleeding were very low and the same in all three treatment arms (n = 1; 1%). There was a slight increase in the mean endometrial thickness in all three groups, which remained less than 5 mm.CONCLUSIONS: The ultra-low-dose combination of E2/NETA 0.1 or E2/NETA 0.25 resulted in a high incidence of amenorrhea and no bleeding in postmenopausal women, and a corresponding high level of compliance. Overall, there was no significant change in mean endometrial thickness during 6 months of active treatment or placebo.

obstetrics & gynecology
Evaluation of effectiveness of Letrozole in treatment of infertility in women with polycystic ovary syndrome

Jasrin Akter Mile,Mashuma Munni,Dilara Rahman,Tahamina Parvin,Shanaz Pervin

DOI: https://doi.org/10.3329/cemecj.v7i1.70827

2024-01-21

Abstract:Background: Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disease, characterized by hyperandrogenism, oligomenorrhea, and polycystic ovaries. PCOS is one of the most causes that affect the women of childbearing age, and often leads to infertility. Various managements were proposed for infertile women with PCOS. However, the optimal management option has not been addressed satisfied. Although multiple treatments including weight reduction, clomiphene citrate, metformin, gonadotropins, and ovary cauterization have been reported to treat such condition, the efficacy still has insufficient evidence to support. Objectives: Purpose of this study was to evaluate the effectiveness of Letrozole in treatment of infertility in women with polycystic ovary syndrome. Materials & method: This study was carried out to assess the effectiveness of letrozole and on pregnancy outcomes including the ovulation induction, pregnancy rate, and endometrial thickness in infertile women with polycystic ovarian syndrome (PCOS). Total 106 infertile PCOS patients were recruited and allocated in two groups, Group-L (received letrozole at 2.5 mg twice daily on the 3rd–5th days of menstrual cycle for 5 consecutive days), Group-G 75 U/d−1 gonadotropin through intramuscular injection for 5 days starting from the third day of menstrual cycle). All patient in both arm completed treatment and follow-up. Patients in both groups were treated up to 5 treatment cycles. During follow up, transvaginalultrasonogram (TVS) was performed to see the details of the follicles and the endometrium. Data was processed and analysed with the help of computer program SPSS and Microsoft excel. Quantitative data expressed as mean and standard deviation and qualitative data as frequency and percentage. Comparison was done by tabulation and graphical presentation in the form of tables, pie chart, graphs, bar diagrams, histogram & charts etc. Result: Mean age of the patient was 26.3 ± 5.7 years in group-L and 25.9 ± 6.1 years in group-G. There were no statistical significant differences between the 2 groups regarding age, body weight, height, body mass index (BMI). Present study results showed that patients who received letrozole exert better outcomes in primary endpoint, including ovulation rate (86.7% in group-L & 62.2% in group-G, P =0.004), endometrial thickness (9.3 ± 1.1 mm in group-L & 8.5 ± 1.1 mm in group-G, P = 0.003) and pregnancy rate (64.1% in group-L & 30.1% in group-G, P =0.005). Abortion rate (till the end of 12th week) and multiple pregnancy rate were higher in group-G, but result were non-significant in between groups. Live birth rate in the letrozole group was higher 29(54.7%) than group-G 14(26.4%), the difference was statistically significant (P < .05). Conclusion: Patients who took Letrozole had significantly higher endometrial thickness than other group. Due to the higher pregnancy rate and lower incidence of abortion or multiple pregnancy, letrozole can be an effective for the treatment of anovulatory subfertility of the PCOS patients. Central Medical College Journal Vol 7 No 1 January 2023 Page: 13-19
[Pharmacobezoar of the stomach as a complication of treatment of duodenal ulcer (author's transl)].

A. Wiernikowski,J. Bogdał,M. Klasa

Abstract:
The Effectiveness of Letrozole Alone or in Combination with Methotrexate in the Management of Ectopic Pregnancy, A Systematic Review and Meta-Analysis

Ghaemi, Marjan

DOI: https://doi.org/10.1007/s43032-024-01712-7

2024-10-10

Reproductive Sciences

Abstract:This systematic review and meta-analysis aimed to investigate the effect of letrozole alone or in combination with Methotrexate on the management of ectopic pregnancy. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were applied for reporting. The EMBASE, PubMed, Scopus, and Web of Science databases were searched for relevant studies focused on women diagnosed with ectopic pregnancy and managed non-surgically with letrozole alone or in combination with methotrexate (MTX) until April 2024. The success rate, laboratory findings, and complications were analyzed and reported. Meta-analysis was done using RevMan 5.4.1 software. Out of 129 unique studies obtained, 7 of them were found eligible for final review; of which, 3 were nonrandomized prospective cohort studies, 2 were randomized clinical trials, and 2 study were case studies. In 5 studies letrozole was used as monotherapy. While in another study letrozole was used with MTX. The meta-analysis showed a significantly lower level of β-HCG in the letrozole group compared to MTX, 7 days after initiation of treatment (Fixed effect model, MD = -92.22, 95%CI: [-159.39, -25.04], P = 0.007, I2 = 0%). There was no significant difference in the level of anti-mullerian hormone (AMH) between groups (Fixed effect model, MD = 0.18, 95%CI: [-0.09, 0.45], P = 0.20, I2 = 0%). Success rate, platelet count, and level of liver enzymes seemed to be better or similar among patients receiving Letrozole compared to patients receiving Methotrexate. Letrozole exhibits potential as a therapeutic option for ectopic pregnancies; however, further randomized clinical trials are necessary to establish strong evidence.

obstetrics & gynecology,reproductive biology
Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial

Juan A Garcia-Velasco,Guillermo Quea,Manuel Piró,Mercedes Mayoral,María Ruiz,Mónica Toribio,Antonio Requena

DOI: https://doi.org/10.1016/j.fertnstert.2008.04.042

Abstract:Objective: To investigate the effect of letrozole-an oral aromatase inhibitor-on E(2), P, and LH levels when administered during the luteal phase after oocyte retrieval in IVF/intracytoplasmic sperm injection (ICSI) cycles. Design: Prospective, randomized, placebo controlled trial. Setting: University-affiliated private reproductive medicine center. Patient(s): Thirty oocyte donors undergoing standardized controlled ovarian hyperstimulation (COH) protocols. Intervention(s): Patients were randomized after successful egg retrieval to receive either 2.5 mg of letrozole (Femara; Novartis, Barcelona, Spain) or a placebo (folic acid tablets). All donors were under intrauterine device (IUD) contraception. Main outcome measure(s): Serum E(2), P, and LH the day of hCG administration and days +4, +7 and +10 after ovum pick-up. Result(s): Donors had a comparable serum E(2) level on the day of hCG administration (1,858 vs. 2,143 pg/mL). Interestingly, levels dramatically dropped 4 days after egg retrieval, reaching a statistically significant lower level in those receiving letrozole (279 vs. 1,586 pg/mL). Again, at the next time points serum E(2) levels were significantly lower (day +7: 240 vs. 855 pg/mL and day +10: 40 vs. 448 pg/mL). No significant differences were observed in P levels, but LH serum concentrations were lower in the control group on day +7 (0.18 vs. 0.02 mIU/mL and day +10 (0.40 vs. 0.16 mIU/mL), when serum E(2) levels were higher. Conclusion(s): The administration of 2.5 mg of letrozole during the luteal phase has an impact on corpus luteum (CL) function. It reduces serum E(2) levels, which allows a faster recovery of LH concentration. This may be of interest not only for egg donors, but also in patients at high risk of ovarian hyperstimulation syndrome (OHSS) who freeze all their embryos or who cancel hCG administration to reduce the potential risk that high E(2) levels pose.
Small doses of human chorionic gonadotropin prevent estradiol-induced luteolysis.

P. K. Westfahl,L. Horton,H. Stadelman,J. Resko

DOI: https://doi.org/10.1152/AJPENDO.1984.247.1.E84

1984-07-01

Abstract:The manner in which exogenous 17 beta-estradiol (E2) induces premature luteolysis in primates is unclear. In an effort to determine whether exogenous luteotropic hormone inhibits E2-induced luteolysis, E2 capsules were implanted subcutaneously in 11 cynomolgus macaques during the early luteal phase; six animals received injections of human chorionic gonadotropin (hCG; 7.5, 10, or 15 IU/day) for 10 days, and the remaining monkeys received saline. Blood was collected once daily for measurement of E2, progesterone, and bioactive luteinizing hormone (LH). Peak progesterone concentrations were between 0.7 and 5.0 ng/ml and declined prematurely in monkeys given E2 plus saline; the luteal phase was 11.5 +/- 0.6 days (mean +/- SE). With E2 plus hCG treatment, serum progesterone continued to increase after E2 capsule placement and reached peak levels of 4.0-13.0 ng/ml; the luteal phase was 15.3 +/- 0.5 days. Therefore, E2-induced luteolysis was overcome by concurrent administration of hCG. These results suggest that exogenous tropic hormone circumvents the inhibitory influence of E2 on luteal function, but the details of the interaction remain unknown.

Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties.

Wireless wideband SAW sensor - antenna design

Low-flow mediated constriction incorporated indices as indicators of cardiovascular risk in smokers.

Hepatitis B immune globulin (HBIG): efficacy in the interruption of vertical transmission of hepatitis B virus (HBV) carrier state.

Letrozole Stimulation in Endometrial Preparation for Cryopreserved–thawed Embryo Transfer in Women with Polycystic Ovarian Syndrome: A Pilot Study

Letrozole Combined With Oral Contraceptives Versus Oral Contraceptives Alone In The Treatment Of Endometriosis-Related Pain Symptoms: A Pilot Study

Efficacy of N-Acetylcysteine on Endometriosis-Related Pain, Size Reduction of Ovarian Endometriomas, and Fertility Outcomes

Comparing the effectiveness of letrozole versus methotrexate for treatment of ectopic pregnancy: A randomized controlled trial

Does Nomegestrol Acetate Plus 17β-Estradiol Oral Contraceptive Improve Endometriosis-Associated Chronic Pelvic Pain in Women?

Beta3-adrenoceptor is involved in the inhibition of small intestinal motility due to restraint stress in rats.

Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer.

Electronic structure of the neutral manganese acceptor in gallium arsenide.

Efficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysis

Randomized,blind,parallel-controlled and multiple-centre clinical trial on the effectiveness and safety of leuprolide acetate in the treatment of endometriosis

A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

Evaluation of effectiveness of Letrozole in treatment of infertility in women with polycystic ovary syndrome

[Pharmacobezoar of the stomach as a complication of treatment of duodenal ulcer (author's transl)].

The Effectiveness of Letrozole Alone or in Combination with Methotrexate in the Management of Ectopic Pregnancy, A Systematic Review and Meta-Analysis

Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial

Small doses of human chorionic gonadotropin prevent estradiol-induced luteolysis.